[{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Series A Financing","leadProduct":"Gene therapy","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genespire","amount2":0.02,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0.02,"dosageForm":"","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"1","companyTruncated":"Genespire \/ Sofinnova Partners"},{"orgOrder":0,"company":"Genespire","sponsor":"Genespire","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2020","type":"Collaboration","leadProduct":"MicroRNA-regulated lentiviral vectors","moa":"","graph1":"Genetic Disease","graph2":"Undisclosed","graph3":"Genespire","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"","sponsorNew":"Genespire \/ Genespire","highestDevelopmentStatusID":"1","companyTruncated":"Genespire \/ Genespire"},{"orgOrder":0,"company":"Genespire","sponsor":"Sofinnova Partners","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"ITALY","productType":"Cell and Gene therapy","year":"2024","type":"Series B Financing","leadProduct":"GENE202","moa":"","graph1":"Genetic Disease","graph2":"IND Enabling","graph3":"Genespire","amount2":0.050000000000000003,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Genetic Disease","amount2New":0.050000000000000003,"dosageForm":"","sponsorNew":"Genespire \/ Sofinnova Partners","highestDevelopmentStatusID":"5","companyTruncated":"Genespire \/ Sofinnova Partners"}]

Find Clinical Drug Pipeline Developments & Deals by Genespire

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : The financing will enable the development of GENE202, the company’s lead candidate, up to a Phase I/II clinical trial patients affected by methylmalonic acidemia.

                          Product Name : GENE202

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          September 24, 2024

                          Lead Product(s) : GENE202

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : IND Enabling

                          Sponsor : Sofinnova Partners

                          Deal Size : $52.0 million

                          Deal Type : Series B Financing

                          blank

                          02

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : Under the terms of the alliance, Genespire and SR-Tiget will study and further develop novel gene therapies, which have the unique potential to address severe unmet medical need and exploit gene editing and lentiviral vector technologies developed by SR-...

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          May 13, 2020

                          Lead Product(s) : MicroRNA-regulated lentiviral vectors

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Recipient : SR-Tiget

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank

                          03

                          Biotech Digital Meet
                          Not Confirmed
                          Biotech Digital Meet
                          Not Confirmed

                          Details : The funds will be used to advance Genespire’s leading-edge platform technologies towards the development of novel gene therapies in primary immunodeficiencies and metabolic genetic diseases.

                          Product Name : Undisclosed

                          Product Type : Cell and Gene therapy

                          Upfront Cash : Undisclosed

                          April 29, 2020

                          Lead Product(s) : Gene Therapy

                          Therapeutic Area : Genetic Disease

                          Highest Development Status : Undisclosed

                          Sponsor : Sofinnova Partners

                          Deal Size : $17.3 million

                          Deal Type : Series A Financing

                          blank